‘Doing more with less’: In-house counsel on budgets and strategy

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

22 December 2025 Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.

Biotechnology

An update on patenting in Ukraine, Russia and Eurasia

2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

Biotechnology

WATCH: Mastering the art of IP transactions—due diligence, valuation, and deal-making

8 July 2025 LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

‘Doing more with less’: In-house counsel on budgets and strategy

More on this story

Editor's picks

Editor's picks

More features